Business Standard

Covishield vaccine to be sold only after successful trial: Serum Institute

SII issued this clarification after reports in the media began appearing which claimed that Covishield- Oxford University's vaccine candidate, will be commercialised in a little over two months

Coronavirus, vaccine, covid, drugs, Sepsivac, clinical trials
Premium

The phase three trials for the Oxford vaccine candidate are being conducted by SII in India.

Press Trust of India Bengaluru
The current claims over the coronavirus vaccine, Covishield, are completely false and it will be commercialised when trials prove successful and regulatory approvals are in place, said Serum Institute of India (SII) on Sunday.

SII issued this clarification after reports in the media began appearing which claimed that Covishield- Oxford University's vaccine candidate, will be commercialised in a little over two months.

The phase three trials for the Oxford vaccine candidate are being conducted by SII in India.


"Serum Institute of India clarifies that

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Aug 23 2020 | 5:17 PM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Register to read more on Business-Standard.com